Lv2
106 积分 2025-10-15 加入
Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data
20小时前
已完结
Octreotide and Octreotide-derived delivery systems
4天前
已完结
The history of somatostatin analogs
4天前
求助中
Predictive Factors for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing 177 Lu-PSMA-617 Radioligand Treatment
4天前
已完结
Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises
4天前
求助中
Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours
4天前
求助中
Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide
4天前
求助中
Somatostatin receptor imaging with 123I-Tyr3-octreotide
4天前
已完结
Octreotide, a new somatostatin analogue
4天前
求助中
Birth of the Beta-knife Thyroidectomy: The Radiance of Saul Hertz
4天前
已完结
皖公网安备34019202002308
